An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma (MM) incorporating iberdomide, isatuximab, and dexamethasone – the IBIS study amarc 20-01.
Interim analysis shows promising efficacy of iberdomide, isatuximab, and dexamethasone in FHR multiple myeloma, indicating effective risk-stratification may be achieved.
Key Points
To evaluate the efficacy and safety of the IB-IS-DEX regimen for functional high-risk multiple myeloma.
Conducted a multicenter trial with 50 participants receiving iberdomide, isatuximab, and dexamethasone.
Evaluated overall response rate and safety after 12 cycles.
Performed genomic analyses using circulating tumour DNA to assess mutational spectrum.
Overall response rate reached 69% with significant early disease control.
Progression-free survival estimated at 51% and overall survival at 82% at 9 months.
Frequent adverse events included neutropenia (54%) and insomnia (36%).